CN116056762B - 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 - Google Patents
包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 Download PDFInfo
- Publication number
- CN116056762B CN116056762B CN202180055398.7A CN202180055398A CN116056762B CN 116056762 B CN116056762 B CN 116056762B CN 202180055398 A CN202180055398 A CN 202180055398A CN 116056762 B CN116056762 B CN 116056762B
- Authority
- CN
- China
- Prior art keywords
- 5meodmt
- benzoate
- composition
- xrpd
- batch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411802400.4A CN119613319A (zh) | 2020-06-12 | 2021-06-14 | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 |
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008961.1A GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
| GB2008964.5 | 2020-06-12 | ||
| GBGB2008964.5A GB202008964D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
| GB2008961.1 | 2020-06-12 | ||
| GBGB2008968.6A GB202008968D0 (en) | 2020-06-12 | 2020-06-12 | Phamaceutical composition |
| GB2008968.6 | 2020-06-12 | ||
| GB2019241.5A GB2596884B8 (en) | 2020-06-12 | 2020-12-07 | A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| GB2019241.5 | 2020-12-07 | ||
| GBGB2101634.0A GB202101634D0 (en) | 2021-02-05 | 2021-02-05 | Pharmaceutical composition |
| GB2101634.0 | 2021-02-05 | ||
| GB2101640.7 | 2021-02-05 | ||
| GBGB2101640.7A GB202101640D0 (en) | 2021-02-05 | 2021-02-05 | Pharmaceutical composition |
| GB2102100.1 | 2021-02-15 | ||
| GBGB2102095.3A GB202102095D0 (en) | 2021-02-15 | 2021-02-15 | Pharmaceutical composition |
| GBGB2102100.1A GB202102100D0 (en) | 2021-02-15 | 2021-02-15 | Pharmaceutical composition |
| GB2102095.3 | 2021-02-15 | ||
| GBGB2105047.1A GB202105047D0 (en) | 2021-04-08 | 2021-04-08 | Pharmaceutical composition |
| GBGB2105049.7A GB202105049D0 (en) | 2021-04-08 | 2021-04-08 | Pharmaceutical composition |
| GB2105049.7 | 2021-04-08 | ||
| GB2105047.1 | 2021-04-08 | ||
| GB2105462.2 | 2021-04-16 | ||
| GBGB2105462.2A GB202105462D0 (en) | 2021-04-16 | 2021-04-16 | Pharmaceutical composition |
| PCT/GB2021/051475 WO2021250434A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411802400.4A Division CN119613319A (zh) | 2020-06-12 | 2021-06-14 | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116056762A CN116056762A (zh) | 2023-05-02 |
| CN116056762B true CN116056762B (zh) | 2024-12-24 |
Family
ID=76641719
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180055398.7A Active CN116056762B (zh) | 2020-06-12 | 2021-06-14 | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 |
| CN202411802400.4A Pending CN119613319A (zh) | 2020-06-12 | 2021-06-14 | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411802400.4A Pending CN119613319A (zh) | 2020-06-12 | 2021-06-14 | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US11518743B2 (https=) |
| EP (5) | EP3941583B9 (https=) |
| JP (2) | JP7795482B2 (https=) |
| KR (1) | KR20230024378A (https=) |
| CN (2) | CN116056762B (https=) |
| AU (1) | AU2021289147A1 (https=) |
| BR (1) | BR112022025306A2 (https=) |
| CA (1) | CA3187020A1 (https=) |
| DK (1) | DK4279070T3 (https=) |
| ES (1) | ES3007386T3 (https=) |
| FI (1) | FI4279070T3 (https=) |
| IL (1) | IL298871A (https=) |
| NZ (1) | NZ795865A (https=) |
| WO (2) | WO2021250434A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| BR112022025306A2 (pt) | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| BR112023024688A2 (pt) * | 2021-05-26 | 2024-02-15 | Mindset Pharma Inc | Combinação de halucinógeno-ácido graxo |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| EP4373807A1 (en) | 2021-07-22 | 2024-05-29 | GH Research Ireland Limited | Method for preparing a tryptamine derivative |
| EP4159192A1 (en) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| US20230099972A1 (en) * | 2021-09-30 | 2023-03-30 | ATAI Life Sciences AG | Compositions and methods for treating headaches |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4448488A2 (en) * | 2021-12-13 | 2024-10-23 | Beckley Psytech Limited | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| CN118984868A (zh) | 2021-12-31 | 2024-11-19 | 恩派瑞安神经科学公司 | 用于产生精神药物生物碱的遗传修饰的生物体 |
| EP4463153A4 (en) * | 2022-01-12 | 2026-03-04 | Eleusis Therapeutics Us Inc | Psilocin benzoate formulation for intravenous infusion |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2023186837A1 (en) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Treatment of postnatal depression |
| WO2023186834A1 (en) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Crystalline hydrobromide salt of 5-meo-dmt |
| IL315899A (en) * | 2022-03-27 | 2024-11-01 | Gh Res Ireland Limited | 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CA3267555A1 (en) * | 2022-10-26 | 2024-05-02 | Atai Therapeutics, Inc. | Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use |
| WO2024105379A1 (en) * | 2022-11-14 | 2024-05-23 | Beckley Psytech Limited | Formulations of 5-meo-dmt |
| GB202306256D0 (en) | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2024256821A1 (en) | 2023-06-13 | 2024-12-19 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
| WO2025024637A1 (en) * | 2023-07-25 | 2025-01-30 | Atai Therapeutics, Inc. | Compositions for limiting sympathomimetic effects of psychedelic therapeutics |
| WO2025068714A1 (en) * | 2023-09-28 | 2025-04-03 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
| WO2025153822A1 (en) | 2024-01-18 | 2025-07-24 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) powder formulations |
| WO2026068950A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders |
| WO2026068953A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | Methods and kits comprising 5-meo-dmt for use in treating depression |
| WO2026068951A1 (en) * | 2024-09-27 | 2026-04-02 | Beckley Psytech Limited | 5-methoxy-dmt for use in the treatment of depression |
| WO2026078143A1 (en) * | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2774763A (en) | 1956-12-18 | Preparation of amides of lysergic age | ||
| US2997470A (en) | 1956-03-05 | 1961-08-22 | Lilly Co Eli | Lysergic acid amides |
| US3078214A (en) | 1958-09-12 | 1963-02-19 | Sandoz Ag | Treatment of mental disturbances with esters of indoles |
| GB981192A (en) | 1960-03-30 | 1965-01-20 | Westminster Bank Ltd | Improvements in or relating to 4 hydroxytryptamine esters |
| US3224945A (en) | 1963-05-06 | 1965-12-21 | College Of Pharmacy | Process for the production of ergot alkaloids |
| BE792515A (fr) | 1971-12-10 | 1973-06-08 | Sandoz Sa | Nouveaux derives de l'acide lysergique, leur preparation et leur application comme medicaments |
| CH578565A5 (en) | 1972-12-07 | 1976-08-13 | Sandoz Ag | N-(2-amino-5-pyridyl) lysergic acid amides - with saluretic and serotonin antagonist activity |
| HU172649B (hu) | 1975-04-24 | 1978-11-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh biologicheski aktivnykh lizergamidov |
| GB1584464A (en) | 1977-04-19 | 1981-02-11 | Farmaceutici Italia | Ergot alkaloids |
| EP0026899A1 (de) | 1979-10-09 | 1981-04-15 | Sandoz Ag | Peptidergotalkaloide, Verfahren zu deren Herstellung, diese enthaltende pharmakologische Zusammensetzungen und ihre Anwendung bei der therapeutischen Behandlung |
| AU6917400A (en) * | 1999-08-31 | 2001-03-26 | Alcon Laboratories, Inc. | Use of 5-ht1b/1d agonists to treat otic pain |
| WO2002038141A2 (en) | 2000-11-08 | 2002-05-16 | Massachusetts Institute Of Technology | Compositions and methods for treatment of mild cognitive impairment |
| KR100523257B1 (ko) * | 2000-12-29 | 2005-10-24 | 삼성전자주식회사 | 포지티브형 감광성 폴리이미드 전구체 및 이를 포함하는조성물 |
| DK1523486T3 (da) | 2002-06-21 | 2008-03-03 | Suven Life Sciences Ltd | Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet |
| WO2008003028A2 (en) | 2006-06-28 | 2008-01-03 | Chelsea Therapeutics, Inc. | Pharmaceutical compositions comprising droxidopa |
| WO2008051599A2 (en) * | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil |
| EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| WO2010054202A2 (en) | 2008-11-06 | 2010-05-14 | Leon Rosenberg | Package of pills useful for titration and method of titrating a patient |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| CA2816595C (en) * | 2010-10-07 | 2018-11-27 | Eaglepharma Pty Ltd | Combination therapy for the treatment of depression and other non-infectious diseases |
| EP2771341A4 (en) * | 2011-10-28 | 2015-09-23 | Univ Texas | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| CN103816150A (zh) | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
| US20180147142A1 (en) | 2015-05-19 | 2018-05-31 | Joseph Robert Knight | Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids |
| US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| MX2020009254A (es) | 2018-03-08 | 2021-01-15 | New Atlas Biotechnologies Llc | Procesos para la produccion de triptaminas. |
| US10813116B2 (en) | 2018-05-11 | 2020-10-20 | Apple Inc. | Support of advanced user equipment (UE) minimum processing times in new radio (NR) systems |
| CA3148256A1 (en) | 2018-06-21 | 2019-12-26 | Robert John Petcavich | Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases |
| US11045454B2 (en) | 2018-12-06 | 2021-06-29 | Palo Alto Investors LP | Methods of treating food allergy conditions |
| SG11202106207VA (en) | 2018-12-14 | 2021-07-29 | Pear Therapeutics Inc | A digital therapeutic component to optimize induction of buprenorphine-containing products |
| FI4349407T3 (fi) * | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| HUE069534T2 (hu) | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| MX2021010198A (es) | 2019-02-27 | 2021-09-21 | Univ California | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. |
| CA3132731A1 (en) | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20220304980A1 (en) * | 2019-07-04 | 2022-09-29 | SW Holdings, Inc | Metered dosing compositions and methods of use of psychedelic compounds |
| GB201911024D0 (en) * | 2019-08-01 | 2019-09-18 | Beckley Found | Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders |
| EP4017859A4 (en) | 2019-08-25 | 2023-08-23 | Caamtech, LLC | ALKYL QUARTERNARY AMMONIUM TRYPTAMINE AND THEIR THERAPEUTIC USES |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| MX2022012537A (es) | 2020-04-16 | 2022-11-07 | Pike Therapeutics Inc | Entrega transdermica de microdosis de derivados psicodelicos. |
| US20210322743A1 (en) | 2020-04-20 | 2021-10-21 | Indian Institute Of Technology Bombay | Microneedle array patch for drug delivery and production method thereof |
| US20230210762A1 (en) | 2020-05-01 | 2023-07-06 | Emergex USA Corporation | Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions |
| WO2021225796A1 (en) | 2020-05-05 | 2021-11-11 | Universitätsspital Basel | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics |
| BR112022025306A2 (pt) | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN113288883A (zh) | 2021-05-24 | 2021-08-24 | 河南科技大学 | 一种长效缓解抑郁微针贴片及其制备方法 |
-
2021
- 2021-06-14 BR BR112022025306A patent/BR112022025306A2/pt unknown
- 2021-06-14 CA CA3187020A patent/CA3187020A1/en active Pending
- 2021-06-14 IL IL298871A patent/IL298871A/en unknown
- 2021-06-14 EP EP21735379.6A patent/EP3941583B9/en active Active
- 2021-06-14 EP EP21735380.4A patent/EP3941904A1/en not_active Withdrawn
- 2021-06-14 CN CN202180055398.7A patent/CN116056762B/zh active Active
- 2021-06-14 AU AU2021289147A patent/AU2021289147A1/en active Pending
- 2021-06-14 EP EP23157604.2A patent/EP4279070B1/en active Active
- 2021-06-14 KR KR1020237001336A patent/KR20230024378A/ko active Pending
- 2021-06-14 CN CN202411802400.4A patent/CN119613319A/zh active Pending
- 2021-06-14 NZ NZ795865A patent/NZ795865A/en unknown
- 2021-06-14 EP EP24213283.5A patent/EP4483957A3/en active Pending
- 2021-06-14 WO PCT/GB2021/051475 patent/WO2021250434A1/en not_active Ceased
- 2021-06-14 FI FIEP23157604.2T patent/FI4279070T3/fi active
- 2021-06-14 DK DK23157604.2T patent/DK4279070T3/da active
- 2021-06-14 EP EP24208163.6A patent/EP4595962A3/en active Pending
- 2021-06-14 WO PCT/GB2021/051476 patent/WO2021250435A1/en not_active Ceased
- 2021-06-14 JP JP2022576811A patent/JP7795482B2/ja active Active
- 2021-06-14 ES ES23157604T patent/ES3007386T3/es active Active
-
2022
- 2022-04-27 US US17/660,981 patent/US11518743B2/en active Active
- 2022-04-27 US US17/660,873 patent/US11518742B2/en active Active
- 2022-08-04 US US17/817,548 patent/US11603353B2/en active Active
- 2022-09-26 US US17/935,256 patent/US11680044B2/en active Active
-
2023
- 2023-02-01 US US18/162,976 patent/US20230348381A1/en active Pending
- 2023-05-02 US US18/310,822 patent/US20230382858A1/en not_active Abandoned
-
2025
- 2025-12-18 JP JP2025264947A patent/JP2026048894A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116056762B (zh) | 包含5-甲氧基-n,n-二甲基色胺的苯甲酸盐的组合物 | |
| AU2022413759A1 (en) | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| CN115974757A (zh) | 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物 | |
| WO2023186826A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| US6075028A (en) | Method of treating Tourette's syndrome and related CNS disorders | |
| WO2025068714A1 (en) | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) | |
| JP2026506513A (ja) | 産後うつ病の処置における５－メトキシ－ｎ，ｎ－ジメチルトリプタミン | |
| JP2026505778A (ja) | 産後うつ病の処置における５－ｍｅｏ－ｄｍｔの使用 | |
| KR20240134951A (ko) | 트립타민 조성물 및 방법 | |
| KR20250097837A (ko) | 펜에틸아민 화합물, 조성물, 및 사용 방법 | |
| US20260035334A1 (en) | Method of synthesis | |
| US20260041667A1 (en) | Prescription digital therapeutics | |
| US20250221963A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| CN121729226A (zh) | 用于治疗兴奋剂成瘾的药物 | |
| JP2022501419A (ja) | 鎮痛組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |